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The Patient Protection and Affordable Care Act requires that health care insurers cover routine patient costs
associated with participating in clinical trials for cancer and other life-threatening diseases. There is a need to
better deﬁne routine costs within the context of hematopoietic stem cell transplantation (HSCT) clinical trials.
This white paper presents guidance on behalf of the American Society for Blood and Marrow Transplantation
for deﬁning a standard HSCT episode and delineates components that may be considered as routine patient
costs versus research costs. The guidelines will assist investigators, trial sponsors, and transplantation centers
in planning for clinical trials that are conducted as a part of the HSCT episode and will inform payers who
provide coverage for transplantation.
 2015 American Society for Blood and Marrow Transplantation.BACKGROUND
Clinical research and clinical trials are critical to improving
patient survival and outcomes after hematopoietic stem cell
transplantation (HSCT). HSCT is a complex procedure that
includes several phases of care from the pretransplantation
workup to long-term post-transplantation follow-up. Within
these episodes, there are multiple opportunities for clinical
trials to evaluate novel therapies and improve HSCT
procedures. Examples include, but are not limited to, in-
vestigations of newer conditioning regimens, graft manipu-
lation, supplemental cellular therapies, and interventions to
prevent or treat post-transplantation complications. However,
it can be challenging to differentiate routine care as part of thedgments on page 588.
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ty for Blood and Marrow Transplantation.HSCT episode from care that is provided as part of a clinical
trial.
With implementation of the Patient Protection and
Affordable Care Act (ACA) health care insurers are pro-
hibited from denying patients’ participation in an approved
clinical trial for cancer or other life-threatening disease.
Now, payers must cover routine patient costs associated
with participating in these clinical trials. However, to
assure appropriate payment for costs associated with
clinical trials involving HSCT, we need to know what con-
stitutes routine patient care costs versus clinical research
costs in such trials. There is a need to better deﬁne a
standard episode for HSCT to guide patients, health care
providers, transplantation centers, and payers about com-
ponents of transplantation care that may be considered
routine versus those that may be considered investiga-
tional. Martin et al. have recently provided a perspective
on coverage of costs associated with patient participation
in cancer clinical trials [1].
N.S. Majhail et al. / Biol Blood Marrow Transplant 21 (2015) 583e588584The American Society for Blood and Marrow Trans-
plantation (ASBMT) established a task force comprising ex-
perts in HSCT, including transplantation clinical trials,
payers, and patient advocates. The task force presents this
white paper as consensus guidelines for deﬁning a standard
HSCT episode (that is, routine patient care) and delineates
components that may be considered clinical research costs. It
will assist transplantation centers in planning for clinical
trials that are conducted as a part of the HSCT episode and
will inform payers who provide coverage for transplantation.
CLINICAL TRIAL COVERAGE UNDER THE ACA
The ACA provision for cancer clinical trial coverage went
into effect in January 2014 (www.healthcare.gov and
www.dol.gov/ebsa/healthreform/). In essence, it is designed
to provide a greater opportunity for clinical trial participation
for patients with cancer or other life-threatening diseases and
prohibits health plans or insurance issuers from denying
coverage or discriminating on the basis of participation in an
approved clinical trial. An approved clinical trial is deﬁned as a
phase I, II, III, or IV trial for the prevention, detection, or
treatment of cancer or other life-threatening disease or con-
dition (life-threatening disease or condition is one from which
the likelihood of death is probable unless the course of the
disease or condition is interrupted). It includes federally fun-
ded trials, trials conducted under an investigational new drug
(IND) application reviewed by the Food and Drug Adminis-
tration (FDA), or drug trials exempt from having an IND
application. The law directs payers to cover routine patient
costs associated with participation in a clinical trial.
The statue provides a broad deﬁnition of routine patient
costs, and includes items and services consistent with the
coverage provided in the health plan that typically would be
covered for a qualiﬁed individual who is not enrolled in a
clinical trial. Excluded from the deﬁnition of routine patient
costs are (1) costs of the investigational item, device, or
service itself; (2) costs of items and services that are provided
solely to satisfy data collection and analysis needs and that
are not used in the direct clinical management of the patient;
and (3) costs of a service that is clearly inconsistent with
widely accepted and established standards of care for a
particular diagnosis.
GUIDING PRINCIPLES
The task force recognizes the complexity of clinical trials
performed as part of HSCT. General guidelines are presented
in this document and individual clinical trials will need to be
reviewed to determine routine care versus research. The
following guiding principles were considered in the devel-
opment of these recommendations:
 Clinical trials are critical to advancing the ﬁeld of HSCT
and for improving patient outcomes. Care for HSCT
recipients should ideally be provided on well-designed
and high-impact clinical trials.
 General guidance is presented as it is not possible to
envision and incorporate all HSCT clinical trial sce-
narios. Each clinical trial will need an individual
assessment of what constitutes routine clinical care
versus research.
 Guidelines will need to be reviewed and updated
periodically so that they are reﬂective of the state of the
art research being conducted in HSCT.
 Guidelines focus on research conducted as part of the
autologous or allogeneic HSCT episode. This paper doesnot provide guidance on clinical trials of cellular ther-
apies or other clinical interventions that do not include
HSCT (see below for deﬁnition of HSCT).
 The terms standard care or routine care can create am-
biguity for the purposes of deﬁning coverage as the
“standard” can change over time or vary among trans-
plantation centers. Instead, reasonable and medically
necessary is a better term to describe items and services
that are required for the direct clinical management of
the patient [1]. However, to be consistent with the
terminology included in the ACA, we have used the
term routine care in this manuscript.
 Phase I, II, III, and IV clinical trials for the prevention,
detection, or treatment of cancer and life-threatening
diseases as deﬁned under the ACA are considered; for
example, these guidelines do not apply to research that
is conducted using existing data (eg, retrospective or
registry studies).
 The clinical trial protocol and the study’s stated hy-
potheses, aims, and endpoints should be used as a
reference to guide and inform coverage decisions.
 The guidelines apply to a reasonable period of time
after transplantation when the majority of a patient’s
post-transplantation care can be expected to occur at
the transplantation center. However, clinical trials may
include interventions or assessments that extend
beyond this time period. Investigators, transplantation
centers, and study sponsors should delineate care that
is considered standard versus investigational for the
duration of the study.
 There exists considerable variation in the models and
coverage of care for long-term transplantation survi-
vors. At some centers, patients may continue to be
followed at the transplantation center long-term for
routine follow-up or for the management of
transplantation-related complications (eg, chronic
graft-versus-host disease). Clinical trials in this popu-
lation will need to be reviewed individually to deter-
mine what may be considered as routine care and what
components may be research.
 It is not uncommon for currently available drugs to be
used for off-label indications in HSCT recipients. For
example, graft-versus-host disease in allogeneic HSCT
recipients is not an FDA-approved indication for most
drugs that are commonly used for the prevention or
treatment of this complication. Other examples include
use of palifermin to prevent mucositis for allogeneic
recipients or use of antitumor necrosis factor agents to
treat steroid-refractory graft-versus-host disease.
Outside of clinical trials that are speciﬁcally investi-
gating such agents, we view that this utilization should
be considered as part of covered beneﬁts.
 Clinical trials may compare transplantation with non-
transplantation therapies. These guidelines can be
applied to the transplantation component of such
clinical trials.SPECIAL CONSIDERATIONS FOR HSCT CLINICAL TRIAL
COVERAGE
The task force considered situations such as new or
emerging indications for which transplantation is not
considered as standard therapy. Some examples include
investigation of transplantation for autoimmune diseases
such as multiple sclerosis, systemic sclerosis, inﬂammatory
Table 1
Recommended Procedure Terms for HSCT Patient Care Episode (from LeMaistre et al. [2])
Term Deﬁnition
HSCI Infusion of a product (bone marrow, peripheral blood stem cells, cord blood) that contains HPCs, often characterized
by CD34 expression.
HSCT An episode of care starting with a preparative regimen and continuing through HSCI and recovery.
Allogeneic HSCT HSCI using products collected from a donor and usually following a preparative regimen. Donors may be a biological
relative of the recipient or anonymous and unrelated.
Syngeneic HSCT HSCI using products collected from an identical sibling.
Autologous HSCT HSCI using products collected from the recipient before myeloablative chemotherapy.
Tandem transplantation The patient receives a second preparative regimen, along with HPCs collected during the initial mobilization.
Both transplantations are planned in advance and typically are performed a few weeks to a few months apart.
DCI An infusion of cells from an allogeneic donor typically given after HSCT. Types of cells used for DCI include, but
are not limited to, the lymphocytes/T cells (donor lymphocyte infusion), peripheral blood mononuclear cells
(both stimulated and unstimulated), dendritic cells from the original donor, or mesenchymal cells.
Supplemental infusion An infusion of cells given before clinical day 0 (day of HSCT) for any reason other than to produce engraftment.
An infusion of supplemental cells is often given in conjunction with a preparative regimen for HSCT.
Retransplantation HSCT after undergoing a previous transplantation.
Subsequent (boost) infusion Subsequent transfusion of allogeneic or autologous HPCs.
HSCI indicates hematopoietic stem cell infusion; HPC, hematopoietic progenitor cells; DCI, donor cell infusion.
N.S. Majhail et al. / Biol Blood Marrow Transplant 21 (2015) 583e588 585bowel disease, and systemic lupus erythematous, or for a
new prognostic marker that may adversely affect survival in
patients with diseases that are considered as standard indi-
cation for transplantation (eg, new molecular marker for
acute myeloid leukemia). HSCT may be considered as the
application of routine therapy to a new or emerging indica-
tion in such circumstances and not the development of an
entirely new treatment. Alternatively, clinical trials may
focus on HSCT approaches that are routinely used in clinical
practice and considered as standard of care. An example is a
phase III clinical trial comparing 2 commonly used condi-
tioning regimens, where the majority of clinical care pro-
vided under the trial may be considered as routine care.
Although it was beyond our scope to envision all HSCT clin-
ical trial scenarios, the task force generally recommends a
similar approach for deﬁning a standard HSCT episode forTable 2
Guidelines for Deﬁning Standard HSCT Episode of Care
Treatment Phase Examples of Components Considered Part
Standard HSCT Episode
Evaluation (Transplantation
consultation and evaluation)
- Transplantation consultation
- HLA typing of related and, if applicable,
donors and/or umbilical cord blood unit
Pretransplantation care
(Pretransplantation workup)
- Evaluation of disease status (eg, bone m
CT scan, serum protein electrophoresis)
- Evaluation of organ function (eg, liver fu
echocardiogram, pulmonary function te
- Psychosocial assessment
- Other evaluations to determine recipien
(eg, consultation with a specialist, addit
tests to evaluate abnormal ﬁndings)
- Assessments to determine related or un
donor suitability and eligibility
Transplantation event (From start
of conditioning regimen to
30-120 d after transplantation)
- Mobilization and collection of periphera
blood or bone marrow HPCs
- Conditioning regimen chemotherapy
and/or radiation therapy
- Hospitalization and/or outpatient visits
with administration of conditioning reg
- Infusion of bone marrow, peripheral blo
or umbilical cord blood HPCs
- Hospitalization and/or outpatient
post-transplantation supportive care
- Management of HSCT-related complicat
Follow-up care phase
(Extends through discharge
from transplantation center)
- Hospitalization or outpatient supportive
- Management of HSCT-related complicat
CT indicates computed tomography.HSCT clinical trials (eg, the HSCT procedure itself and the
associated usual pre- and post-transplantation care may be
considered as routine care in clinical trials that are evaluating
new or emerging indications, comparison of 2 trans-
plantation regimens, or a transplantation and non-
transplantation treatment, and investigations of supportive
care interventions). However and as noted above, each
clinical trial will need to be evaluated individually and study
investigators, transplantation centers, trial sponsors, and
payers are encouraged to engage early in the trial develop-
ment process to address the issue of routine versus investi-
gational, where it is relevant.
All interested parties should be aware that the interpre-
tation of the deﬁnitions of routine patient costs and coverage
determinations for clinical trial services may vary among
insurance providers and by region. For example, a clinicalof Examples of Components Considered Research
unrelated
(s)
- Evaluations that are not part of routine care and
are performed speciﬁcally to determine eligibility
or to meet the requirements for a clinical trial
arrow biopsy,
nction tests,
sts)
t suitability
ional
related
- Evaluations that are not part of routine care and
are performed speciﬁcally to determine eligibility
or to meet the requirements for a clinical trial
l
associated
imen
od
ions
- Drug administered under FDA’s IND application
- Cellular therapy product administered under FDA’s
IND application
- Evaluations that are not part of routine care and are
performed speciﬁcally to meet the requirements of a
clinical trial
care
ions
- Evaluations that are not a part of routine care and
are performed speciﬁcally to meet the requirements
of a clinical trial
Table 3
Examples to Provide Guidance on Implementing Deﬁnition of Standard HSCT Episode of Care in the Context of a Clinical Trial
Clinical Trial Evaluation Phase Pretransplantation Care Phase Transplantation Event Phase Follow-Up Care Phase
BMT CTN 0601
Design: Phase II
Title: Unrelated donor reduced-
intensity bone marrow
transplantation for children with
severe sickle cell disease
Type: Testing efﬁcacy and toxicity
of an established transplantation
technique for a new indication
Routine care
- Transplantation consultation
- HLA typing of unrelated donors
Routine care
- Evaluation of disease status and organ func-
tion, psychosocial assessments and any other
evaluations performed by the center to
determine recipient and donor suitability for
transplantation
Routine care
- Collection of donor bone marrow
- Conditioning regimen chemotherapy
speciﬁed in the clinical trial protocol
- Hospitalization and/or outpatient
visits associated with administration
of conditioning regimen and post-
transplantation supportive care
- GVHD prophylaxis regimen speciﬁed
in the clinical trial protocol
- Patient visits and clinic assessments
that are routine care
- Management of HSCT-related
complications
Routine care
- Hospitalization or outpatient
supportive care
- Evaluation and management
of HSCT-related complications,
including GVHD and late effects
Research
- None
Research
- Center effort associated with registering
and enrolling patient on the trial
Research
- Center effort associated with
performing HRQOL assessments
- Center effort associated with
performing endpoint and adverse
event assessment and reporting
Research
- Center effort associated with
performing HRQOL assessments
- Center effort associated with
performing adverse event assess-
ment and reporting for the duration
of the study (2 yr)
BMT CTN 0901
Design: Phase III
Title: A randomized, phase III
study of allogeneic stem cell
transplantation comparing
regimen intensity in patients
with myelodysplastic syndrome
or acute myeloid leukemia
Type: Comparing standard
transplantation treatment
regimens
Routine care
- Transplantation consultation
- HLA typing of related and, if
applicable, unrelated donors
Routine care
- Evaluation of disease status and organ func-
tion, psychosocial assessments and any other
evaluations performed by the center to
determine recipient and donor suitability
Routine care
- Mobilization and collection of donor
PBSCs or collection of donor bone
marrow
- Conditioning regimen chemotherapy
and TBI speciﬁed in the clinical trial
protocol
- Hospitalization and/or outpatient
visits associated with administration
of conditioning regimen and post-
transplantation supportive care
- GVHD prophylaxis regimen speciﬁed
in the clinical trial protocol
- Patient visits and clinic assessments
that are routine care
- Management of HSCT-related
complications
Routine care
- Hospitalization or outpatient
supportive care
- Evaluation and management
of HSCT-related complications
including GVHD and late effects
Research
- None
Research
- Center effort associated with registering
and enrolling patient on the trial
Research
- Blood samples for future research
- Center effort associated with
performing HRQOL assessments
- Center effort associated with
performing endpoint and adverse
event assessment and reporting
Research
- Center effort associated with
performing HRQOL assessments
- Center effort associated with
performing endpoint and adverse
event assessment and reporting for
the duration of the study (4 yr)
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be covered through another state law. Alternatively, federal
or state regulations and coverage mechanisms may deter-
mine clinical trial coverage for transplantation. For example,
a state Medicaid program may limit clinical trial participa-
tion to transplantation centers within the state. Another
example is coverage for transplantation for myelodysplastic
syndromes by Centers for Medicare and Medicaid Services
under its Coverage with Evidence Development mechanism.
A scenario that deserves special mention is when a fed-
eral agency or another regulatory body mandates that the
HSCT procedure or certain components of the HSCT proce-
dure be performed on a clinical trial protocol for additional
data collection or for other regulatory purposes. An example
is the IND application through the FDA for a multicenter
access and distribution protocol for unlicensed cry-
opreserved umbilical cord blood units, which provides access
to these units for patients in the United States through the
National Marrow Donor Program. The FDA may grant an
exemption to allow cost recovery for a drug (including bio-
logical products) that is being provided under an IND
application. An example for this mechanism is the use of a
well-proven therapy in a new population or through a
modiﬁcation of an established approved therapy such that
the FDA allows the patient’s insurance provider to be billed
for its costs (eg, collection of CD34 selected peripheral blood
stem cells in pediatric donors or using a new technology).
The Centers for Medicare and Medicaid Services Coverage
with Evidence Development mechanism for providing
coverage for myelodysplastic syndromes is another example
of when a federal agency has mandated further data collec-
tion under a clinical trial protocol before it can provide a
deﬁnitive coverage decision. Hence, in appropriate situations
where the HSCT procedure or its components are performed
under an investigational mandate (eg, IND or Investigational
Device Exemption application through the FDA), the proce-
dure and/or pre- and post-transplantation care may be
considered routine patient care. However, in these situations,
payers would not be expected to cover the costs of services
and care that is not “routine” and not used in direct clinical
management of the patient (eg, data collection and analysis
for the examples listed above).
Investigators and transplantation centers routinely un-
dertake the process of identifying routine versus investiga-
tional portions of a trial during the contractual and
budgeting stage and some institutional review boards may
request this information to be submitted as part of their re-
view procedure. The task force encourages investigators to
also specify in study protocols these components of the trial
that may be considered routine care or investigational.
Transplantation programs are also encouraged to establish
center-speciﬁc guidelines, as needed. Outlining the center
speciﬁc approaches may aid in building consensus with
payers and help in the planning of clinical trials.
We encourage transplantation centers to engage payers
as early as possible in the transplantation evaluation process
for a patient as coverage determination for the HSCT proce-
dure can take time, especially when care is being provided
within the context of a complex clinical trial.
Trial sponsors, transplantation centers, and payers are
encouraged to work together using the framework provided
in this document to determine routine patient care and costs
associated with patient participation in a clinical trial before
the trial is opened for enrollment. Transplantation centers
will also need to educate patients considering participation
N.S. Majhail et al. / Biol Blood Marrow Transplant 21 (2015) 583e588588in a clinical trial to ensure they understand coverage for the
trial based on their health plan. In addition, more and clearer
guidance on the deﬁnition of routine patient care costs from
federal authorities in charge of implementing the ACAwould
be helpful to patients, trial sponsors, transplantation centers,
and payers.
DEFINITION OF HSCT EPISODE
Standard deﬁnitions ofHSCT patient care episode that have
been proposed by the ASBMT and the National Marrow
Donor Program are presented in Table 1 [2].
PHASES OF HSCT EPISODE
For the purposes of payer coverage, the HSCT episode is
frequently divided into several phases, as follows.
Evaluation
The evaluation phase includes services required to assess
and evaluate whether a patient and, in the case of allogeneic
HSCT, the donor, are suitable for the transplantation proce-
dure. It may also include evaluations to assess whether a
transplantation is an appropriate treatment option for the
patient.
Pretransplantation Care
The pretransplantation care phase involves care provided
from the time a patient is identiﬁed as a candidate for HSCT
and includes all related care until the initiation of condi-
tioning regimen.
Transplantation Event
The transplantation event phase usually starts from the
day of starting conditioning regimen and it can last from 30
to 120 days after transplantation. This phase covers the he-
matopoietic stem cell infusion and the transplantation hos-
pitalization, and it also typically includes graft procurement,
stem cell mobilization, and processing. In some situations,
this phase can extend for a longer period of time (eg, tandem
transplantation for germ cell tumors or multiple myeloma).
This phase also includes any clinic visits associated with
providing care to patients receiving an outpatient
transplantation.
Follow-Up Care
The follow-up care phase starts on completion of the
transplantation event phase and can extend until the patient
is discharged from routine transplantation center follow-up
care.
Of note, there may be a gap between the evaluation phase
and the pretransplantation care phase, especially for diseases
where a transplantation is not required immediately (eg,
myelodysplastic syndromes or myeloﬁbrosis) and in situa-
tions where the patient may need more therapy before a
transplantation can proceed. Also, some services may be
included in different phases depending on payer and insti-
tutional preference (eg, donor search or umbilical cord blood
acquisition costs may be considered in the pre-
transplantation care phase, the transplantation event phase,
or as an item that is invoiced separately).
The phases described above reﬂect payer perspective for
coverage of the HSCT episode. Patients need routine long-
term follow-up care after the “HSCT episode” has been
completed. Some examples of such care include assessments
for disease status, evaluation and management of chronic
graft-versus-host disease, providing post-transplantationvaccinations and screening, and evaluation and treatment
of late complications. Such long-term follow-up care for
transplantation recipients should be considered routine care
and not investigational.Deﬁnition of Phases of HSCT Episode
Table 2 presents the phases of an HSCT episode and the
components within each phase that may be considered as
routine clinical care for HSCT recipients. To assist with the
interpretation of these guidelines, some examples based on
ongoing Blood and Marrow Clinical Trials Network clinical
trials are presented in Table 3.PUBLIC COMMENTS
The draft white paper was circulated to the ASBMT
membership for public comments. Based on comments
provided by several individuals, this ﬁnal draft clariﬁes that
HSCT recipients need follow-up for screening, prevention,
and management of late complications of transplantation
and this long-term care should be considered as routine care.
Several commenters suggested that we provide additional
guidance on HSCT that are performed under a clinical trial to
fulﬁll regulatory requirements but where the HSCT proce-
dure would be considered as routine care; the ﬁnal draft has
clariﬁed and provides several examples to address this
comment. Other commenters requested that speciﬁc exam-
ples of clinical trial scenarios be provided (eg, which T cell
depletion methods are routine care versus research); the
task force felt that such detailed guidance on speciﬁc trans-
plantation technologies and care practices was beyond the
scope of this white paper. In response to other comments, we
have emphasized that care for HSCT recipients should ideally
be provided under clinical trials. There were comments that
discussed the inﬂuence of HSCT clinical trials on quality and
costs, the “value” of transplantation as a treatment, and
certain payer issues around clinical trials coverage (eg, role of
reinsurers in determining coverage); these issues were
considered by the task force to be beyond the scope of this
white paper. However, we believe that the guidance pro-
vided in this paper will facilitate further conversations about
these important issues. One commenter voiced reservations
about our recommendation that HSCT not be considered as
development of an entirely new treatment in cases of new or
emerging indications. The task force had considerable debate
on this issue and ultimately decided to take the stated
approach due to several factors. Some examples include the
lack of speciﬁc federal guidance on how to deﬁne routine care
under the ACA, the nuances of deﬁning a “new” indication for
transplantation, and the analogy of using HSCT as “off-label”
therapy in such circumstances. A separate initiative from this
task force will be providing guidance on indications for
transplantation.ACKNOWLEDGMENTS
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